1. Review the history and biology of the Ras oncogene.
2. Discuss prior drug development strategies in anti-Ras therapy.
3. Present recent trial data on a KRAS (G12C) inhibitor.
Thursday, February 13, 2020 - 8:00am to 9:15am
Michael J. Breen, M.D., Ph.D.
Evanston Hospital, Room G870
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation